Ulcerative Colitis

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis

Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study

Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis

Pfizer's Ulcerative Colitis Candidate Aces Late-Stage Study

Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study

Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis

Ulcerative Colitis Recent News

Ventyx Jumps Over 20% Today After NASDAQ Debut

Less than a year ago, Ventyx Biosciences Inc (NASDAQ: VTYX) emerged from stealth mode, then last month, it sprinted to Wall Street with a $100 million IPO ticket.

Bristol Myers' TYK2 Inhibitor Disappoints In Mid-Stage Ulcerative Colitis Study

Why Did Kaleido Shares Plunge 10% On Tuesday?

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients

Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients.

AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis

Analysts Slash Price Targets After Theravance's Failed Ulcerative Colitis Study

Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ: TBPH) after disappointing ulcerative colitis Phase 2 trial data.

Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study

Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Galapagos Shares Drop As SIK Inhibitor Fails To Show Positive Outcomes In Ulcerative Colitis, Rheumatoid Arthritis Patients

Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis

Eli Lilly's Mirikizumab Shows Mucosal Healing In Ulcerative Colitis Maintained For Up To One Year

Bristol-Myers' Zeposia Scores FDA Approval For Ulcerative Colitis

Progenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis

Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia

Eli Lilly Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications

I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study

Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms

Eli Lilly and Co's (NYSE: LLY) Mirikizumab is now one step closer to get approval after

AbbVie's Humira Gets FDA Approval For Pediatric Ulcerative Colitis

AbbVie's Upadacitinib Shows Clinical Benefit In Second Late-Stage Ulcerative Colitis Study

Here's Why Arena Pharmaceuticals Jumped 30% Tuesday

Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally